Ken Frazier, AP Images
It's not just about Keytruda, Merck insists, as it carves out assets worth $6.5B into new company
As sales of Merck’s flagship therapy Keytruda grow from strength to strength — the New Jersey drugmaker is spinning off its women’s health, legacy brands, and biosimilar drugs into a new company.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
